Cannabis and Cannabinoids in Adults with Cancer
Publication Date: March 13, 2024
Last Updated: March 14, 2024
Treatment
Clinical Communication and Education
Recommendation 1.1
Health systems and clinicians, in partnership, should provide adults with cancer unbiased, evidence-based cannabis and/or cannabinoid educational resources to facilitate clinical communication, informed decision-making, and systematized approaches to care. (GPS, , , )
3499376
Recommendation 1.2
Given the high prevalence of cannabis and/or cannabinoid use among adults with cancer, clinicians should routinely and non-judgmentally inquire about cannabis use (or consideration of use), and either guide care or direct adults with cancer to appropriate resources. (GPS, , , )
Note. Clinicians should remain sensitive to cannabis regulations’ disproportionate impacts on marginalized communities and work to omit cannabis-related and other biases (e.g., racial, ethnic, and socioeconomic) from clinical discussions about cannabis and/or cannabinoids. Table 1 offers suggestions for cannabinoid history-taking.
3499376
Recommendation 1.3
When adults with cancer use cannabis and/or cannabinoids outside of evidence-based indications or clinician recommendations, clinicians should explore goals, educate, and seek to minimize harm. (GPS, , , )
3499376
Title
Cannabis and Cannabinoids in Adults with Cancer
Authoring Organization
American Society of Clinical Oncology